Close Menu

Clostridium difficile

The school will use the NIH money to study the genetics involved in how the pathogen infects people and how it interacts with the gut microbiota.

Asuragen, Life Tech launch BCR/ABL1 Quant test in Europe; Palex Medical to distribute Molecular Detection’s MRSA assay in Spain; Meridian Biosciences gets FDA nod for C. difficile molecular amplification assay.

The illumigene C. difficile molecular amplification test is Meridian's first molecular diagnostic product.

Molecular Detection's Detect-Ready MRSA test; Diatherix Laboratories' GI panel; DNA test for early Lyme disease at Connecticut's Milford Hospital

Meridian Bioscience's Illumigene C. difficile test; Nanosphere's Verigene SP respiratory virus panel; Veredus Laboratories' VereFlu test and VereID Biosystem; and IMDx's 2009 influenza H1N1 assay

The C. difficile test is the first molecular diagnostic product for Meridian. It hopes to market the test later this year.

Kettering Health Network hopes to cut costs by using Diatherix's PCR-based infectious disease tests.

British, French, and American researchers reported that they have sequenced and compared different strains of Clostridium difficile in an attempt to find genetic causes for the bug's increased virulence.

Pages

23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.

China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.

In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.

NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.